Univariate logistic regression analysis of predictors of hypertension remission in unilateral primary aldosteronism patients based on preoperative data in the training cohort
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| Age, y | 0.964 (0.937-0.992) | .012 |
| Female sex | 4.720 (2.282-9.766) | < .001 |
| Duration of hypertension, y | 0.938 (0.891-0.986) | .012 |
| BMI, kg/m2 | 0.794 (0.705-0.895) | < .001 |
| SBP, mm Hg | 0.977 (0.958-0.996) | .018 |
| ARR, pg.mL–1/mU.L–1 | 1.788 (1.328-2.407) | < .001 |
| PAC post-SIT, pg/mL | 1.723 (1.154-2.574) | .008 |
| DDD of antihypertensive medication | 0.779 (0.569-1.066) | .118 |
| Absence of target organ damage | 0.199 (0.082-0.486) | < .001 |
| Absence of medical history of diabetes | 0.228 (0.089-0.582) | .002 |
| Size of largest nodule at imaging, mm | 0.997 (0.932-1.066) | .921 |
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| Age, y | 0.964 (0.937-0.992) | .012 |
| Female sex | 4.720 (2.282-9.766) | < .001 |
| Duration of hypertension, y | 0.938 (0.891-0.986) | .012 |
| BMI, kg/m2 | 0.794 (0.705-0.895) | < .001 |
| SBP, mm Hg | 0.977 (0.958-0.996) | .018 |
| ARR, pg.mL–1/mU.L–1 | 1.788 (1.328-2.407) | < .001 |
| PAC post-SIT, pg/mL | 1.723 (1.154-2.574) | .008 |
| DDD of antihypertensive medication | 0.779 (0.569-1.066) | .118 |
| Absence of target organ damage | 0.199 (0.082-0.486) | < .001 |
| Absence of medical history of diabetes | 0.228 (0.089-0.582) | .002 |
| Size of largest nodule at imaging, mm | 0.997 (0.932-1.066) | .921 |
Data are expressed as odds ratio (OR) (95% CI).
Abbreviations: ARR, aldosterone-to-renin ratio; BMI, body mass index; DDD, defined daily dose; HT, hypertension; PAC, plasma aldosterone concentration; SBP, systolic blood pressure; SIT, saline infusion test.
Univariate logistic regression analysis of predictors of hypertension remission in unilateral primary aldosteronism patients based on preoperative data in the training cohort
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| Age, y | 0.964 (0.937-0.992) | .012 |
| Female sex | 4.720 (2.282-9.766) | < .001 |
| Duration of hypertension, y | 0.938 (0.891-0.986) | .012 |
| BMI, kg/m2 | 0.794 (0.705-0.895) | < .001 |
| SBP, mm Hg | 0.977 (0.958-0.996) | .018 |
| ARR, pg.mL–1/mU.L–1 | 1.788 (1.328-2.407) | < .001 |
| PAC post-SIT, pg/mL | 1.723 (1.154-2.574) | .008 |
| DDD of antihypertensive medication | 0.779 (0.569-1.066) | .118 |
| Absence of target organ damage | 0.199 (0.082-0.486) | < .001 |
| Absence of medical history of diabetes | 0.228 (0.089-0.582) | .002 |
| Size of largest nodule at imaging, mm | 0.997 (0.932-1.066) | .921 |
| Variable . | OR (95% CI) . | P . |
|---|---|---|
| Age, y | 0.964 (0.937-0.992) | .012 |
| Female sex | 4.720 (2.282-9.766) | < .001 |
| Duration of hypertension, y | 0.938 (0.891-0.986) | .012 |
| BMI, kg/m2 | 0.794 (0.705-0.895) | < .001 |
| SBP, mm Hg | 0.977 (0.958-0.996) | .018 |
| ARR, pg.mL–1/mU.L–1 | 1.788 (1.328-2.407) | < .001 |
| PAC post-SIT, pg/mL | 1.723 (1.154-2.574) | .008 |
| DDD of antihypertensive medication | 0.779 (0.569-1.066) | .118 |
| Absence of target organ damage | 0.199 (0.082-0.486) | < .001 |
| Absence of medical history of diabetes | 0.228 (0.089-0.582) | .002 |
| Size of largest nodule at imaging, mm | 0.997 (0.932-1.066) | .921 |
Data are expressed as odds ratio (OR) (95% CI).
Abbreviations: ARR, aldosterone-to-renin ratio; BMI, body mass index; DDD, defined daily dose; HT, hypertension; PAC, plasma aldosterone concentration; SBP, systolic blood pressure; SIT, saline infusion test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
